Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

Bosutinib may be a first-line option for patients with chronic phase chronic myeloid leukemia (CML), according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1
Data from the BFORE study showed significantly higher 12-month major molecular remission (MMR) and complete cytogenetic response (CCyR) with bosutinib (ClinicalTrials.gov Identifier: NCT02130557) compared with imatinib.
Although the responses were higher, they came at a price — higher incidence of gastrointestinal events and transaminase elevations.
BFORE is an ongoing, multinational phase 3 study where 536 patients with chronic phase CML were randomly assigned to receive bosutinib 400 mg daily (268 patients) or imatinib 400 mg daily (268 patients).
MMR at 12 months was significantly higher with bosutinib: 47.2% vs 36.9% with imatinib (P = .02). A similar pattern was seen for CCyR (at 12 months, 77.2% with bosutinib vs 66.4% with imatinib).
Rates of BCR-ABL transcripts less than 10% at 3 months were 75% for bosutinib and 57% for imatinib.
Although this is an initial read-out, cumulative incidence of event-free survival events at 12 months was lower with bosutinib (3.7% vs 6.4% for imatinib).
One patient on bosutinib and 6 on imatinib died during treatment.
Safety data were consistent with what has been reported for bosutinib. Most of the gastrointestinal events were grade 1 to 2 and did not require treatment discontinuation. Higher incidence of grade 3 or worse events with bosutinib included diarrhea (8% vs 1%) and levels of alanine (19% vs 2%) and aspartate (10% vs 2%) transaminase.
“Bosutinib could become a welcome new front-line treatment option for patients with [chronic phase] CML,” Dr Cortes concluded
Source:http://www.cancertherapyadvisor.com/chronic-myeloid-leukemia/chronic-leukemia-cml-bosutinib-imatinib-first-line-treatment/article/667062/

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more